279 related articles for article (PubMed ID: 23987739)
1. Challenging and complex decisions in the management of the BRCA mutation carrier.
Stan DL; Shuster LT; Wick MJ; Swanson CL; Pruthi S; Bakkum-Gamez JN
J Womens Health (Larchmt); 2013 Oct; 22(10):825-34. PubMed ID: 23987739
[TBL] [Abstract][Full Text] [Related]
2. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
3. Should risk-reducing surgery in women from hereditary breast ovarian cancer families be confined to removal of the fallopian tubes with ovarian conservation?
Snyder CL; Casey MJ; Lynch HT
Womens Health (Lond); 2015 Jul; 11(4):423-7. PubMed ID: 26246179
[No Abstract] [Full Text] [Related]
4. Surgical decision making in premenopausal
Gaba F; Goyal S; Marks D; Chandrasekaran D; Evans O; Robbani S; Tyson C; Legood R; Saridogan E; McCluggage WG; Hanson H; Singh N; Evans DG; Menon U; Manchanda R;
J Med Genet; 2022 Feb; 59(2):122-132. PubMed ID: 33568437
[TBL] [Abstract][Full Text] [Related]
5. Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial.
van Driel C; de Bock GH; Schroevers MJ; Mourits MJ
BJOG; 2019 Feb; 126(3):402-411. PubMed ID: 30222235
[TBL] [Abstract][Full Text] [Related]
6. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
7. [Genetical aspects of surgical treatment in patients with hereditary breast cancer].
Bit-Sava EM
Vestn Khir Im I I Grek; 2014; 173(5):27-30. PubMed ID: 25823331
[TBL] [Abstract][Full Text] [Related]
8. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies.
Long KC; Kauff ND
Curr Opin Oncol; 2011 Sep; 23(5):526-30. PubMed ID: 21734577
[TBL] [Abstract][Full Text] [Related]
9. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
Doren A; Vecchiola A; Aguirre B; Villaseca P
Climacteric; 2018 Dec; 21(6):529-535. PubMed ID: 30295091
[TBL] [Abstract][Full Text] [Related]
10. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know.
De Felice F; Marchetti C; Boccia SM; Romito A; Sassu CM; Porpora MG; Muzii L; Tombolini V; Benedetti Panici P
Cancer Treat Rev; 2017 Dec; 61():1-5. PubMed ID: 29028552
[TBL] [Abstract][Full Text] [Related]
11. Management of ovarian cancer risk in women with
Walker M; Jacobson M; Sobel M
CMAJ; 2019 Aug; 191(32):E886-E893. PubMed ID: 31405835
[No Abstract] [Full Text] [Related]
12. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.
Kwon JS; Tinker A; Pansegrau G; McAlpine J; Housty M; McCullum M; Gilks CB
Obstet Gynecol; 2013 Jan; 121(1):14-24. PubMed ID: 23232752
[TBL] [Abstract][Full Text] [Related]
13. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
Ložar T; Žgajnar J; Perhavec A; Blatnik A; Novaković S; Krajc M
Eur J Surg Oncol; 2021 Aug; 47(8):1900-1906. PubMed ID: 33812767
[TBL] [Abstract][Full Text] [Related]
14. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer.
Schrauder MG; Brunel-Geuder L; Häberle L; Wunderle M; Hoyer J; Reis A; Schulz-Wendtland R; Beckmann MW; Lux MP
Breast; 2017 Apr; 32():186-191. PubMed ID: 28214786
[TBL] [Abstract][Full Text] [Related]
16. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
17. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Gabriel CA; Tigges-Cardwell J; Stopfer J; Erlichman J; Nathanson K; Domchek SM
Fam Cancer; 2009; 8(1):23-8. PubMed ID: 18758995
[TBL] [Abstract][Full Text] [Related]
18. Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
Collins IM; Milne RL; Weideman PC; McLachlan SA; Friedlander ML; ; Hopper JL; Phillips KA
Med J Aust; 2013 Nov; 199(10):680-3. PubMed ID: 24237098
[TBL] [Abstract][Full Text] [Related]
19. Psychological factors associated with the intention to choose for risk-reducing mastectomy in family cancer clinic attendees.
van Driel CMG; Oosterwijk JC; Meijers-Heijboer EJ; van Asperen CJ; Zeijlmans van Emmichoven IA; de Vries J; Mourits MJE; Henneman L; Timmermans DRM; de Bock GH
Breast; 2016 Dec; 30():66-72. PubMed ID: 27639031
[TBL] [Abstract][Full Text] [Related]
20. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR
JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
